ClinicalTrials.gg
CompletedNCT03558997Updated May 28, 2020Results posted

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

A Phase 2 interventional study of Dupilumab and Timothy Grass SCIT in Allergic Rhinitis, sponsored by Regeneron Pharmaceuticals. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.

Enrollment
45th of 119
103 · median 54
Started
2018
with 3 others
Phase 2
17 of 141
1 open now
Registered
123rd of 141
by date

Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 45th largest by enrollment of the 119 interventional ones that give a count, is one of 4 that started in 2018, is one of 17 in phase 2, and was the 123rd registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Rhinitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic rhinitis symptoms, as measured by Total Nasal Symptom Score (TNSS) after nasal allergen challenge (NAC) with Timothy Grass extract at week 17.

The secondary objectives of the study are:

  • To assess whether 16 weeks of treatment with dupilumab as compared to placebo reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract
  • To assess whether 16 weeks of treatment with dupilumab as compared to dupilumab + SCIT reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract
  • To assess changes in serum Timothy-grass-specific immunoglobulin G4 (IgG4), serum Timothy grass-specific immunoglobulin E (IgE), and ratio of serum Timothy Grass-specific IgG4 to IgE over 16 weeks of treatment with dupilumab + SCIT as compared to SCIT monotherapy
  • To evaluate the safety and tolerability of 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass SCIT
03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male and female participants aged 18 to 55
  2. History of grass pollen-induced seasonal allergic rhinitis
  3. Grass pollen allergy confirmed by both:

    1. Positive skin prick test (SPT) with Timothy Grass extract (mean wheal diameter at least ≥5 mm greater than a negative control)
    2. Positive serum Timothy Grass-specific IgE (≥0.35KU/L)

Key Exclusion Criteria:

  1. Significant rhinitis, sinusitis, outside of the grass pollen season
  2. Any to SCIT (i.e, severe cardiovascular disease, , disease, use of beta blocker, asthma severe enough to require chronic medication, acute infection)
  3. Use of systemic within 4 weeks of screening visits or any NAC visits
  4. Abnormal lung function as judged by the investigator
  5. A clinical history of asthma requiring chronic medication such as regular inhaled corticosteroids for >4 weeks per year
  6. History of significant recurrent sinusitis, defined as 3 episodes per year for the last 2 years, all of which required antibiotic treatment
  7. History of chronic sinusitis (with or without nasal polyps)
  8. Tobacco smoking (ANY) within the last year

Note: Other protocol defined inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Placebo

    Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.

    Drug: Placebo matching dupilumab · Drug: Placebo matching SCIT

  • Experimental
    Dupilumab

    Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.

    Drug: Dupilumab · Drug: Placebo matching SCIT

  • Experimental
    SCIT

    Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.

    Drug: Timothy Grass SCIT · Drug: Placebo matching dupilumab

  • Experimental
    Dupilumab + SCIT

    Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.

    Drug: Dupilumab · Drug: Timothy Grass SCIT

Interventions

  • Dupilumab was administered SC in a single-use, pre-filled glass syringe

    Also known as: DUPIXENT®, REGN668, SAR231893

  • DrugTimothy Grass SCIT

    Timothy grass extract was administered SC.

  • DrugPlacebo matching dupilumab

    Placebo matching dupilumab was prepared in the same formulation without the addition of protein

  • DrugPlacebo matching SCIT

    Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing), each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.

    Time frame: Baseline, Week 17

Secondary outcomes

  1. Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.

    Time frame: Baseline, Week 17

  2. Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT group in this outcome measure.

    Time frame: Baseline, Week 17

  3. Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT.

    Time frame: Baseline, Week 17

  4. Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of responses for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.

    Time frame: Baseline, Week 17

  5. Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

    TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.

    Time frame: Baseline, Week 17

  6. Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17

    Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing values were imputed by Last Observation Carried Forward (LOCF) method for visits between post-baseline to Week 17.

    Time frame: Baseline, Week 17

  7. Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17

    Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

    Time frame: Baseline, Week 17

  8. Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17

    Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

    Time frame: Baseline, Week 17

  9. Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17

    Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

    Time frame: Baseline, Week 17

  10. Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17

    Biomarkers measured in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

    Time frame: Baseline, Week 17

  11. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 24\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Baseline through Week 24

07

Results

Posted May 28, 2020

Participant flow

A total of 214 participants were screened for study eligibility at 17 study sites in United States and Canada, of whom 103 were randomized to receive the study treatment. Screen failure was mostly due to inclusion criteria not met/exclusion criteria met.

Participant flow — Overall Study
MilestonePlaceboDupilumabSCITDupilumab + SCIT
Started25262626
Completed24241824
Not completed1282
Withdrew: Adverse event0251
Withdrew: Physician decision0010
Withdrew: Withdrawal by subject1011
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryPercent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing), each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17
Percent ChangeSCITDupilumab + SCIT
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17-56.76 ± 9.687-52.03 ± 8.462
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = 0.7185 · Least square (ls) mean difference: 4.73 · 95% CI -21.023 to 30.487The confidence interval (CI) with p-value was based on treatment difference (Dupilumab + SCIT vs SCIT) of the LS mean using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryChange From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Score on a Scale*hour
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT
Score on a Scale*hourSCITDupilumab + SCIT
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT-3.07 ± 0.361-2.77 ± 0.321
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = 0.5438 · Least square (ls) mean difference: 0.30 · 95% CI -0.661 to 1.254The confidence interval (CI) with p-value was based on treatment difference (Dupilumab + SCIT vs SCIT) of the LS mean using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryChange From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT group in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Score on a Scale*hour
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab
Score on a Scale*hourPlaceboDupilumab
Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab-1.85 ± 0.323-1.83 ± 0.329
Statistical analysis
  • Placebo vs Dupilumab · ANCOVA · p = 0.9559 · Least square (ls) mean difference: 0.03 · 95% CI -0.877 to 0.928The confidence interval (CI) with p-value was based on treatment difference (Dupilumab vs Placebo) of the LS mean using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryPercent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + placebo matched to SCIT and placebo matched to dupilumab + placebo matched to SCIT.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
Percent ChangePlaceboDupilumab
Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17-28.82 ± 8.427-21.57 ± 8.415
Statistical analysis
  • Placebo vs Dupilumab · ANCOVA · p = 0.5416 · Least square (ls) mean difference: 7.25 · 95% CI -16.028 to 30.530The confidence interval (CI) with p-value was based on treatment difference (Dupilumab vs Placebo) of the LS mean using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryChange From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of responses for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Score on a Scale*hour
Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
Score on a Scale*hourDupilumabDupilumab + SCIT
Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17-1.83 ± 0.329-2.77 ± 0.321
Statistical analysis
  • Dupilumab vs Dupilumab + SCIT · ANCOVA · p = 0.0414 · Least square (ls) mean difference: -0.94 · 95% CI -1.848 to -0.037The confidence interval (CI) with p-value was based on treatment difference (Dupilumab + SCIT vs Dupilumab) of LS mean difference using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryPercent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17

TNSS was participant-reported composite symptom assessment of 4 symptoms (rhinorrhea, nasal congestion, nasal itching \& sneezing) each scored on a scale from 0 to 3 where 0 = none, 3 = severe. TNSS total score was calculated as the sum of the response for all 4 individual nasal symptom scores and ranged from 0 to 12, where higher score indicated more severe symptoms. AUC of TNSS/component from time of the first observation to time of the last observation (AUC \[0-1 hr\]) was calculated by using the trapezoid rule. Data was reported for Dupilumab + SCIT and Dupilumab + placebo matched to SCIT group in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17
Percent ChangeDupilumabDupilumab + SCIT
Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17-21.57 ± 8.415-52.03 ± 8.462
Statistical analysis
  • Dupilumab vs Dupilumab + SCIT · ANCOVA · p = 0.0108 · Least square (ls) mean difference: -30.45 · 95% CI -53.874 to -7.034The confidence interval (CI) with p-value was based on treatment difference (Dupilumab + SCIT vs Dupilumab) of LS mean difference using analysis of covariance (ANCOVA) model with baseline measurement as covariate and the treatment as fixed factor.
SecondaryChange From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17

Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing values were imputed by Last Observation Carried Forward (LOCF) method for visits between post-baseline to Week 17.

Time frame:
Baseline, Week 17
Reported as:
Median · Milligram per Liter (mg/L)
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17
Milligram per Liter (mg/L)SCITDupilumab + SCIT
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 171.705 (0.520 to 6.090)3.550 (0.630 to 8.250)
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = 0.1449 · Median difference: 0.665 · 95% CI -0.770 to 3.2100P-value was based on treatment differences of median change using rank based ANCOVA model with baseline measurement as covariate \& treatment as fixed factors. Median difference \& its 95% CI estimated with Hodges-Lehmann method.
SecondaryPercent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17

Measurement of Timothy Grass specific IgG4 was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

Time frame:
Baseline, Week 17
Reported as:
Median · Percent Change
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17
Percent ChangeSCITDupilumab + SCIT
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 171444.49 (650.00 to 2650.00)1896.25 (700.00 to 5050.00)
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = 0.1231 · Median difference: 335.3 · 95% CI -551.47 to 1746.55P-value was based on treatment differences of median change using rank based ANCOVA model with baseline measurement as covariate \& treatment as fixed factors. Median difference \& its 95% CI estimated with Hodges-Lehmann method.
SecondaryChange From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17

Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

Time frame:
Baseline, Week 17
Reported as:
Median · Kilo Unit per Liter (kU/L)
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17
Kilo Unit per Liter (kU/L)SCITDupilumab + SCIT
Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 176.460 (2.750 to 15.900)-2.990 (-10.890 to -0.940)
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = <0.0001 · Median difference: -13.325 · 95% CI -23.9400 to -8.3600P-value was based on treatment differences of median change using rank based ANCOVA model with baseline measurement as covariate \& treatment as fixed factors. Median difference \& its 95% CI estimated with Hodges-Lehmann method.
SecondaryPercent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17

Measurement of Timothy Grass specific sIgE was performed in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

Time frame:
Baseline, Week 17
Reported as:
Median · Percent Change
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17
Percent ChangeSCITDupilumab + SCIT
Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 1781.27 (21.27 to 179.41)-56.44 (-68.00 to -37.20)
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = <0.0001 · Median difference: -134.6 · 95% CI -205.51 to -94.98P-value was based on treatment differences of median change using rank based ANCOVA model with baseline measurement as covariate \& treatment as fixed factors. Median difference \& its 95% CI estimated with Hodges-Lehmann method.
SecondaryChange From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17

Biomarkers measured in serum or plasma to determine effects on biomarkers of relevant physiological and pathogenic processes. Data was reported for Dupilumab + SCIT and placebo matched to Dupilumab + SCIT monotherapy group in this outcome measure. Missing value was imputed by LOCF method for visits between post-baseline to Week 17.

Time frame:
Baseline, Week 17
Reported as:
Median · Ratio
Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17
RatioSCITDupilumab + SCIT
Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 170.745 (0.210 to 1.400)1.720 (1.360 to 2.130)
Statistical analysis
  • SCIT vs Dupilumab + SCIT · ANCOVA · p = <0.0001 · Median difference: 0.840 · 95% CI 0.4500 to 1.2700P-value was based on treatment differences of median change using rank based ANCOVA model with baseline measurement as covariate \& treatment as fixed factors. Median difference \& its 95% CI estimated with Hodges-Lehmann method.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 24\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPlaceboDupilumabSCITDupilumab + SCIT
Participants with TEAEs21182422
Participants with Serious TEAEs1112

Adverse events

Collected over Adverse event information was collected from the time the informed consent was signed until the participant's last study visit, regardless of seriousness or relationship to investigational product.Treatment-emergent adverse events were reported for the 16-week treatment period and the 8-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/25 (0%)1/25 (4%)19/25 (76%)
Dupilumab0/26 (0%)1/26 (3.8%)16/26 (61.5%)
SCIT0/26 (0%)1/26 (3.8%)23/26 (88.5%)
Dupilumab + SCIT0/26 (0%)2/26 (7.7%)20/26 (76.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboDupilumabSCITDupilumab + SCIT
Bipolar disorderPsychiatric disorders1/250/260/260/26
HypersensitivityImmune system disorders0/250/261/260/26
PyelonephritisInfections and infestations0/250/260/261/26
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/251/260/260/26
AnxietyPsychiatric disorders0/250/260/261/26
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboDupilumabSCITDupilumab + SCIT
Injection site reactionGeneral disorders8/258/2611/2616/26
NasopharyngitisInfections and infestations5/255/261/2610/26
HypersensitivityImmune system disorders0/250/264/268/26
Upper respiratory tract infectionInfections and infestations5/254/261/260/26
Injection site indurationGeneral disorders1/250/265/264/26
Injection site erythemaGeneral disorders1/251/262/264/26
Injection site pruritusGeneral disorders1/250/264/263/26
NauseaGastrointestinal disorders3/250/262/262/26
Viral upper respiratory tract infectionInfections and infestations3/250/260/261/26
HeadacheNervous system disorders3/251/261/261/26

Baseline characteristics

The full analysis set (FAS) included all randomized participants. Efficacy analyses were based on the treatment allocated at randomization (as randomized).

Age, Continuous
Age, Continuous(Years)PlaceboDupilumabSCITDupilumab + SCITTotal
Mean34.6 ± 11.0540.3 ± 11.1937.8 ± 11.2533.0 ± 10.5836.5 ± 11.22
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumabSCITDupilumab + SCITTotal
Female1016141050
Male1510121653
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumabSCITDupilumab + SCITTotal
Hispanic or Latino325111
Not Hispanic or Latino2124212591
Unknown or Not Reported10001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumabSCITDupilumab + SCITTotal
American Indian or Alaska Native00000
Asian22329
Native Hawaiian or Other Pacific Islander00000
Black or African American244212
White2018172176
More than one race12104
Unknown or Not Reported00112
Total nasal symptom score (TNSS) Area under Curve (AUC) [0-1 hour (hr)] at Baseline
Total nasal symptom score (TNSS) Area under Curve (AUC) [0-1 hour (hr)] at Baseline(Score on a Scale*hour)PlaceboDupilumabSCITDupilumab + SCITTotal
Mean5.34 ± 2.1755.03 ± 2.1934.66 ± 1.9874.69 ± 1.7204.93 ± 2.015
Timothy Grass Pollen IgG4
Timothy Grass Pollen IgG4(Miligram per Liter (mg/L))PlaceboDupilumabSCITDupilumab + SCITTotal
Median0.080 (0.080 to 0.210)0.080 (0.080 to 0.170)0.080 (0.080 to 0.190)0.080 (0.080 to 0.210)0.080 (0.080 to 0.210)
Timothy Grass Specific Immunoglobulin E (sIgE)
Timothy Grass Specific Immunoglobulin E (sIgE)(Kilo Unit per Liter (kU/L))PlaceboDupilumabSCITDupilumab + SCITTotal
Median9.640 (3.890 to 37.100)4.810 (1.800 to 17.600)10.300 (3.600 to 20.600)11.250 (3.010 to 17.700)9.180 (3.000 to 20.700)
Log Transformed Timothy Grass Pollen IgG4 vs sIgE ratio
Log Transformed Timothy Grass Pollen IgG4 vs sIgE ratio(Ratio)PlaceboDupilumabSCITDupilumab + SCITTotal
Median-1.970 (-2.390 to -1.460)-1.515 (-2.150 to -1.220)-1.860 (-2.110 to -1.650)-1.975 (-2.340 to -1.170)-1.840 (-2.300 to -1.350)
08

Study locations

17 sites
  • Regeneron Investigational Site
    Los Angeles, California 90025, United States
  • Regeneron Investigational Site
    Mountain View, California 94040, United States
  • Regeneron Investigational Site
    Walnut Creek, California 94598, United States
  • Regeneron Investigational Site
    Baltimore, Maryland 21224, United States
  • Regeneron Investigational Site
    Andover, Massachusetts 01810, United States
  • Regeneron Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Regeneron Investigational Site
    Saint Louis, Missouri 63141, United States
  • Regeneron Investigational Site
    Bellevue, Nebraska 68123, United States
  • Regeneron Investigational Site
    Portland, Oregon 97202, United States
  • Regeneron Investigational Site
    East Providence, Rhode Island 02914, United States
  • Regeneron Investigational Site
    Seattle, Washington 98115, United States
  • Regeneron Investigational Site
    Madison, Wisconsin 53792-9988, United States
  • Regeneron Investigational Site
    Kingston, Ontario K7L 2V7, Canada
  • Regeneron Investigational Site
    Mississauga, Ontario L5A 3V4, Canada
  • Regeneron Investigational Site
    Ottawa, Ontario K1G 6C6, Canada
  • Regeneron Investigational Site
    Toronto, Ontario M4V 1R2, Canada
  • Regeneron Investigational Site
    Québec, Quebec G1V 4W2, Canada
09

References and documents

Publications

  • Kamal MA, Franchetti Y, Lai CH, Xu C, Wang CQ, Radin AR, O'Brien MP, Ruddy M, Davis JD. Pharmacokinetics and Concentration-Response of Dupilumab in Patients With Seasonal Allergic Rhinitis. J Clin Pharmacol. 2022 May;62(5):689-695. doi: 10.1002/jcph.2004. Epub 2022 Jan 6. PubMed 34791679 ↗
  • Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, Laws E, Chung ES, Constant T, Sun Y, Maloney J, Hamilton JD, Ruddy M, Wang CQ, O'Brien MP. Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. J Asthma Allergy. 2021 Aug 16;14:1045-1063. doi: 10.2147/JAA.S318892. eCollection 2021. PubMed 34429614 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in May 2019, 11 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 31 phase 2 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 15, 2018
StartActual
Jun 7, 2018
Primary completionActual
May 14, 2019
CompletionActual
Jun 13, 2019
Results first posted
May 28, 2020
Last update
May 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03558997
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Jun 7, 2018
Primary completion
May 14, 2019
Completion
Jun 13, 2019
Results posted
May 28, 2020
Last update
May 28, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion